DelistingAug 10, 2026, 05:03 PM
Lexaria Bioscience Fights Nasdaq Delisting Notice
AI Summary
Lexaria Bioscience Corp. received a Nasdaq delisting notification on August 4, 2026, for failing to meet the $1.00 minimum bid price requirement. In response, the company completed a reverse stock split on August 3, 2026, and its shares are now trading above the required price. Lexaria has also requested a hearing to appeal the delisting and expects to regain full compliance with Nasdaq rules before any potential hearing, anticipating its shares will continue trading without interruption.
Key Highlights
- Received Nasdaq delisting notification on August 4, 2026.
- Delisting due to failure to maintain $1.00 minimum bid price.
- Completed a reverse stock split on August 3, 2026.
- Shares currently trade above the $1.00 minimum bid price.
- Filed request for a hearing to appeal the delisting determination.
- Expects to regain compliance before any potential hearing date.
- Anticipates shares will remain trading on Nasdaq without interruption.
Price Impact
More from LEXX